BioXcel Therapeutics Provides Update on Recent Developments

Meetings scheduled with FDA in October and November for TRANQUILITY and SERENITY III programs Company strengthens IGALMI™ market exclusivity through receipt of two Notices of Allowance ...

Related Keywords

Vimal Mehta , Scott Stachowiak , David Schull , Brennan Doyle , Erik Kopp , Nasdaq , Bioxceltherapeutics Inc , While The Company , Exchange Commission , Drug Administration , Company Current Report On Form , Trademark Office , Securities Exchange , Globenewswire Inc , Bioxcel Therapeutics Inc , Xcel Therapeutics , Stage Clinical Programs , Moderate Dementia , Probable Alzheimer , Breakthrough Meeting , Negative Syndrome Scale Excitatory Component , Current Report , Home Setting , Agitation Associated , Market Exclusivity Strengthened , Two Notices , Drug Products , Therapeutic Equivalence Evaluations , Orange Book , Private Securities Litigation Reform Act , Securities Act , Securities Exchange Act , Quarterly Report , Bioxcel Therapeutics , Markets ,